EN
中文 EN
The only liquid biopsy-based multi-cancer early detection test to recieve Breakthrough Device Designation from both the FDA and the NMPA.
OverC™ covers 70.000+ methylated loci to enable early detection of esophageal, lung, liver, pancreatic, and ovarian cancer.
Key Features and Benefits

One tube of blood for precise early detection of 5 cancer types




Recommended for Adults Aged 50-75

OverC™ is not suitable for people who have acute infection/inflammation within 14 days, or have recently used anti-tumor drugs, or have a hemorrhagic disorder.


Performance Validations
Clinical Trial Studies

THUNDER Study


● Multi-cancer detection blood test-1 (MCDBT-1) had a sensitivity of 69.1% and a specificity of 98.9% in detecting six cancers.


● MCDBT-1 decreased cancer late-stage incidence by 38.7%‒46.4% and increased 5-year survival rate by 33.1%‒40.4%.

● In parallel, MCDBT-2 was set at a lower specificity but a higher sensitivity than MCDBT-1.




Download Our Product Brochure Here Contact Us
Contact Our Biopharma Team to Learn More
Biomarker Discovery & Translational Research
Clinical Trial Design & Patient Recruitment
Global Capabilities for Clinical Studies
CDx Development & Commercialization
Genomic Data Solutions
ctDNA Monitoring Portfolio
Other
I also want to receive general marketing communications from Burning Rock Dx in addition to the specific information requested here. You may unsubscribe from receiving such general marketing communications at any time.
*Required
By submitting this form, or by checking the box above the “Submit” button (if applicable), you agree that your information will be processed according to Burning Rock’s privacy policy to provide you with the information and/or general marketing communications (if applicable) you have requested here. Burning Rock Dx is committed to protecting and respecting your privacy.
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."